UNSPSC 51112102: Palifermin

This classification denotes a therapeutic fibroblast growth factor with the molecular formula C729H1156N204O207S10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QMS40680K6, more generally known as palifermin. European Medicines Agency schedules palifermin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21058. The term PALIFERMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3, 2002, list 48.

Most nations schedule Palifermin under HS 29332990 and SITC 51573. SMILES:. As of Q4 2014, PALIFERMIN remains the US FDA Preferred Term for this commodity.. Palifermin bears US NLM identifiers UMLS ID C0677829 and NCI Concept Code C2455.

UNSPSC 51112102 Palifermin is a Commodity code covering pharmaceutical products used in cancer treatment and oral mucositis management. State and local governments buy this drug primarily through health and human services agencies and Medicaid programs to support patient care protocols in public health systems and state-funded treatment facilities. Procurement activity under this code reflects broader state pharmacy benefit management strategies, including efforts to establish direct purchasing relationships with pharmaceutical manufacturers and optimize drug acquisition costs outside traditional pharmacy benefit manager and group purchasing organization channels.

The Texas Health and Human Services Commission posted an RFI (No. HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI targets vendors with experience in direct contracting for self-insured employers and government health plans, negotiated net pricing models without rebates, and outcomes-based contracting arrangements. The request reflects Texas HHS's intent to gather market intelligence on direct pharmaceutical supply channels before issuing a formal RFP; no award value, budget ceiling, or formal evaluation criteria were specified in the RFI stage. Recent solicitation activity under this code remains limited to this single documented opportunity from Texas, indicating that palifermin procurement at the state and local level is concentrated within individual health agency formulary management and is not currently the subject of widespread multi-jurisdictional competitive activity.